MedTrace Logo

Mineralocorticoid Receptor Antagonists in Type 2 Diabetes

NCT02809963 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2018-06-01

No results posted yet for this study

Summary

The aim of this study is to investigate the effect of selective blocking of the mineralocorticoid receptor in patients with type 2 diabetes on insulin resistance, lipid metabolism and myocardial function.

Conditions

  • Diabetes Type 2

Interventions

DRUG

Eplerenone

50 mg tablets, oral use.

DRUG

Placebo

50 mg tablets, oral use

Sponsors & Collaborators

  • Herlev Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-30
Primary Completion
2017-11-30
Completion
2017-11-30

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02809963 on ClinicalTrials.gov